We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Cambridge Cognition Holdings PLC | AQSE:COG.GB | Aquis Stock Exchange | Ordinary Share | GB00B8DV9647 |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 54.50 | 51.00 | 58.00 | 54.50 | 54.50 | 54.50 | 0.00 | 06:55:37 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
From Apr 2019 to Apr 2024
TIDMCOG
RNS Number : 0762I
Cambridge Cognition Holdings PLC
25 August 2016
Cambridge Cognition Holdings Plc
('Cambridge Cognition' or the 'Company')
Notice of Results
The neuroscience company Cambridge Cognition Holdings PLC (Cambridge, UK - LSE: COG), which develops and markets near patient technologies for the assessment of brain health to improve the drug development process, will be reporting its interim results for the six months ended 30 June 2016 on Thursday 22 September 2016.
Enquiries:
Cambridge Cognition www.cambridgecognition.com Holdings plc Steven Powell, Chief Tel: 01223 810 700 Executive Officer Nick Walters, Chief Financial Officer finnCap Ltd (Nomad Tel: 020 7220 0500 and Joint Broker) Geoff Nash/Simon Hicks (Corporate Finance) Alice Lane (Corporate Broking) Hybridan LLP (Joint Tel: 020 3764 2341 Broker) Claire Noyce (Corporate Broking)
About Cambridge Cognition
Cambridge Cognition is an international neuroscience company which develops and markets near patient cognitive assessment products to improve the understanding, diagnosis and treatment of neurological and psychiatric disorders.
For over 30 years the company's patented technology has advanced the assessment of cognition to accelerate the development of safe and effective treatments, improve patient outcomes and monitor and manage cognitive health throughout life.
Partners include the world's leading biotechnology and pharmaceutical companies; leading academic institutions; and public-private healthcare providers.
www.cambridgecognition.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
NORBRGDIXBDBGLS
(END) Dow Jones Newswires
August 25, 2016 02:02 ET (06:02 GMT)
1 Year Cambridge Cognition Chart |
1 Month Cambridge Cognition Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
